BerGenBio 
BGBIO is a norwegian clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including immune-evasive, therapy resistant cancers.
The stock is currently in a short term uptrend that could provide a new test of important resistance, where a breakout to the upside could trigger a powerful buy signal.
Sponsored analyst summary:
https://www.trinitydelta.org/research-notes/bemcentinib-nsclc-data-continues-to-impress/
Twitter:
https://twitter.com/bgenbio
Investor Relations:
https://www.bergenbio.com/investors/
BGBIO is a norwegian clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including immune-evasive, therapy resistant cancers.The stock is currently in a short term uptrend that could provide a new test of important resistance, where a breakout to the upside could trigger a powerful buy signal.
Sponsored analyst summary:
https://www.trinitydelta.org/research-notes/bemcentinib-nsclc-data-continues-to-impress/
Twitter:
https://twitter.com/bgenbio
Investor Relations:
https://www.bergenbio.com/investors/
Related publications
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Related publications
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.